Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial

Jessica M Sontrop, Shi-Han Huang, Amit X Garg, Louise Moist, Andrew A House, Kerri Gallo, William F Clark, Jessica M Sontrop, Shi-Han Huang, Amit X Garg, Louise Moist, Andrew A House, Kerri Gallo, William F Clark

Abstract

Objectives: Increased water intake may have a beneficial effect on the kidney through suppression of plasma vasopressin. We examined the effect of increased water intake on plasma copeptin (a marker of vasopressin) over 6 weeks in patients with chronic kidney disease.

Design: Secondary analysis of a randomised controlled parallel-group pilot trial.

Setting: Canada, 2012-2013.

Participants: 28 patients with stage 3 chronic kidney disease randomised (2:1) to a hydration (n=17) or control group (n=11).

Intervention: The hydration group was coached to increase water intake by up to 1.5 L/day for 6 weeks. The control group was asked to maintain regular water intake.

Measures and outcomes: Participants provided blood and 24 h urine samples at baseline and 6 weeks. Change in plasma copeptin was compared within and between study groups.

Results: Participants were 64% male with a mean age of 62 years and an estimated glomerular filtration rate of 40 mL/min/1.73 m(2). Between baseline and 6 weeks, 24 h urine volume increased by 0.7 L/day in the hydration group, rising from 2.3 to 3.0 L/day (p=0.01), while decreasing by 0.3 L/day among controls, from 2.0 to 1.7 L/day (p=0.07); between-group difference: 0.9 L/day (95% CI 0.37 to 1.46; p=0.002). In the hydration group, median copeptin decreased by 3.6 pmol/L, from 15.0 to 10.8 pmol/L (p=0.005), while remaining stable among controls at 19 pmol/L (p=0.76; p=0.19 for the between-group difference in median change); the between-group difference in mean change was 5.4 pmol/L (95% CI -1.2 to 12.0; p=0.11).

Conclusions: Adults with stage 3 chronic kidney disease can be successfully randomised to drink approximately 1 L more per day than controls. This increased water intake caused a significant decrease in plasma copeptin concentration. Our larger 12-month trial will examine whether increased water intake can slow renal decline in patients with chronic kidney disease.

Trial registration number: NCT01753466.

Keywords: 24-hour urine volume; chronic kidney disease; coeptin; glomerular filtration rate; water intake.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Intraindividual change in copeptin between baseline and 6 weeks after randomisation.

References

    1. Bouby N, Fernandes S. Mild dehydration, vasopressin and the kidney: animal and human studies. Eur J Clin Nutr 2003;57(Suppl 2):S39–46. 10.1038/sj.ejcn.1601900
    1. Morgenthaler NG, Struck J, Alonso C et al. . Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112–19. 10.1373/clinchem.2005.060038
    1. Roussel R, Fezeu L, Marre M et al. . Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 2014;99:4656–63. 10.1210/jc.2014-2295
    1. Boertien WE, Meijer E, Zittema D et al. . Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2012;27:4131–7. 10.1093/ndt/gfs070
    1. Boertien WE, Meijer E, Li J et al. . Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 2013;61:420–9. 10.1053/j.ajkd.2012.08.038
    1. Enhörning S, Wang TJ, Nilsson PM et al. . Plasma copeptin and the risk of diabetes mellitus. Circulation 2010;121:2102–8. 10.1161/CIRCULATIONAHA.109.909663
    1. Saleem U, Khaleghi M, Morgenthaler NG et al. . Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 2009;94:2558–64. 10.1210/jc.2008-2278
    1. Stoiser B, Mörtl D, Hülsmann M et al. . Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006;36:771–8. 10.1111/j.1365-2362.2006.01724.x
    1. Yalta K, Yalta T, Sivri N et al. . Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013;167:1750–9. 10.1016/j.ijcard.2012.12.039
    1. Khan SQ, Dhillon OS, O'Brien RJ et al. . C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction. Circulation 2007;115:2103–10. 10.1161/CIRCULATIONAHA.106.685503
    1. Keller T, Tzikas S, Zeller T et al. . Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010;55:2096–106. 10.1016/j.jacc.2010.01.029
    1. Velho G, Bouby N, Hadjadj S et al. . Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 2013;36:3639–45. 10.2337/dc13-0683
    1. Morgenthaler NG, Struck J, Jochberger S et al. . Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43–9. 10.1016/j.tem.2007.11.001
    1. Bouby N, Bachmann S, Bichet D et al. . Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol Ren Physiol 1990;258:F973.
    1. Sugiura T, Yamauchi A, Kitamura H et al. . High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-β. Kidney Int 1999;55:1800–10. 10.1046/j.1523-1755.1999.00443.x
    1. Clark WF, Sontrop JM, Macnab JJ et al. . Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 2011;6:2634–41. 10.2215/CJN.01990211
    1. Sontrop JM, Dixon SN, Garg AX et al. . Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am J Nephrol 2013;37:434–42. 10.1159/000350377
    1. Strippoli GF, Craig JC, Rochtchina E et al. . Fluid and nutrient intake and risk of chronic kidney disease. Nephrology 2011;16:326–34. 10.1111/j.1440-1797.2010.01415.x
    1. Clark WF, Sontrop JM, Huang S-H et al. . The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial. BMJ Open 2013;3:e003666 10.1136/bmjopen-2013-003666
    1. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat 2005;4:287–91. 10.1002/pst.185
    1. Moore CG, Carter RE, Nietert PJ et al. . Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci 2011;4:332–7. 10.1111/j.1752-8062.2011.00347.x
    1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J kidney Dis 2002;39(2 Suppl 1):S1–S266.
    1. Levey AS, Stevens LA, Schmid CH et al. . A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12. 10.7326/0003-4819-150-9-200905050-00006
    1. Moher D, Hopewell S, Schulz KF et al. . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869 10.1136/bmj.c869
    1. Sedgwick P. Randomised controlled trials: balance in baseline characteristics. BMJ 2014;349:g5721 10.1136/bmj.g5721
    1. Meijer E, Bakker SJ, de Jong PE et al. . Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009;88:561–7.
    1. Zittema D, van den Berg E, Meijer E et al. . Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 2014;9:1553–62. 10.2215/CJN.08690813
    1. Meijer E, Bakker SJ, Halbesma N et al. . Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010;77:29–36. 10.1038/ki.2009.397
    1. Meijer E, Casteleijn NF. Riding the waves: evidence for a beneficial effect of increased water intake in autosomal dominant polycystic kidney disease patients? Nephrol Dial Transplant 2014;29:1615–17. 10.1093/ndt/gfu054
    1. Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 2013;9:223–39. 10.1038/nrneph.2013.22
    1. Nagao S, Nishii K, Katsuyama M et al. . Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006;17:2220–7. 10.1681/ASN.2006030251
    1. Wang X, Gattone V, Harris PC et al. . Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005;16:846–51. 10.1681/ASN.2004121090
    1. Torres VE, Chapman AB, Devuyst O et al. . Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407–18. 10.1056/NEJMoa1205511
    1. Bankir L, Bichet DG, Bouby N. Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? Am J Physiol Ren Physiol 2010;299:F917–28. 10.1152/ajprenal.00413.2010
    1. Enhörning S, Bankir L, Bouby N et al. . Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes(Lond) 2012;37:598–603. 10.1038/ijo.2012.88
    1. Goldsmith SR. Vasopressin as vasopressor. Am J Med 1987;82:1213–19. 10.1016/0002-9343(87)90228-2
    1. Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008;118:410–21. 10.1161/CIRCULATIONAHA.108.765289
    1. Wong L. Vasopressin V2 receptor antagonists. Cardiovasc Res 2001;51:391–402. 10.1016/S0008-6363(01)00315-7
    1. Enhörning S, Leosdottir M, Wallström P et al. . Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr 2009;89:400–6. 10.3945/ajcn.2008.26382
    1. Plischke M, Kohl M, Bankir L et al. . Urine osmolarity and risk of dialysis initiation in a chronic kidney disease cohort—a possible titration target? PLoS ONE 2014;9:e93226 10.1371/journal.pone.0093226
    1. Bankir L, Bichet DG. Polycystic kidney disease: an early urea-selective urine-concentrating defect in ADPKD. Nat Rev Nephrol 2012;8:437–9. 10.1038/nrneph.2012.139
    1. Johnson RJ, Rodriguez-Iturbe B, Roncal-Jimenez C et al. . Hyperosmolarity drives hypertension and CKD—water and salt revisited. Nat Rev Nephrol 2014;10:415–20. 10.1038/nrneph.2014.76
    1. Bardoux P, Bichet DG, Martin H et al. . Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003;18:497–506. 10.1093/ndt/18.3.497
    1. Cirillo M. Determinants of kidney dysfunction: is vasopressin a new player in the arena? Epidemiology of atherosclerotic renal artery stenosis as a mirror. Kidney Int 2010;77:5–6. 10.1038/ki.2009.408
    1. Bolignano D, Zoccali C. Vasopressin beyond water: implications for renal diseases. Curr Opin Nephrol Hypertens 2010;19:499–504. 10.1097/MNH.0b013e32833d35cf
    1. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 2010;16(Suppl 1):S37–44. 10.1111/j.1751-7133.2010.00177.x
    1. Fenske W, Wanner C, Allolio B et al. . Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol 2011;22:782–90. 10.1681/ASN.2010070691
    1. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371:1624–32. 10.1016/S0140-6736(08)60695-9
    1. Palmer SC, Wong G, Iff S et al. . Fluid intake and all-cause mortality, cardiovascular mortality, and kidney function: a population-based longitudinal cohort study. Nephrol Dial Transplant 2014;29:1377–84. 10.1093/ndt/gft507
    1. Szinnai G, Mörgenthaler NG, Berneis K et al. . Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007;92:3973–8. 10.1210/jc.2007-0232
    1. Reichlin T, Hochholzer W, Stelzig C et al. . Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009;54:60–8. 10.1016/j.jacc.2009.01.076
    1. Yun AJ, Lee PY, Bazar KA. Clinical benefits of hydration and volume expansion in a wide range of illnesses may be attributable to reduction of sympatho-vagal ratio. Med Hypotheses 2005;64:646–50. 10.1016/j.mehy.2004.07.014
    1. Wang CJ, Grantham JJ, Wetmore JB. The medicinal use of water in renal disease. Kidney Int 2013;84:45–53. 10.1038/ki.2013.23

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe